These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 34655432)

  • 21. Disposition study of the novel dipeptidyl peptidase 4 inhibitor cetagliptin in rats.
    Lu J; Hao Y; Zhang F; Pan H; Ding J; Yu Q; Wang T
    Xenobiotica; 2022 May; 52(5):468-475. PubMed ID: 35708192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.
    Bergman A; Ebel D; Liu F; Stone J; Wang A; Zeng W; Chen L; Dilzer S; Lasseter K; Herman G; Wagner J; Krishna R
    Biopharm Drug Dispos; 2007 Sep; 28(6):315-22. PubMed ID: 17575559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
    He YL
    Clin Pharmacokinet; 2012 Mar; 51(3):147-62. PubMed ID: 22339447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers.
    Lim KS; Cho JY; Kim BH; Kim JR; Kim HS; Kim DK; Kim SH; Yim HJ; Lee SH; Shin SG; Jang IJ; Yu KS
    Br J Clin Pharmacol; 2009 Dec; 68(6):883-90. PubMed ID: 20002082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety, Pharmacokinetics, and Pharmacodynamics of a Dipeptidyl Peptidase-4 Inhibitor: A Randomized, Double-Blinded, Placebo-Controlled Daily Administration of Fotagliptin Benzoate for 14 Days for Type 2 Diabetes Mellitus.
    Wu M; Li QQ; Zhang H; Zhu XX; Li XJ; Li Y; Sun HG; Ding YH
    Clin Pharmacol Drug Dev; 2021 Jun; 10(6):660-668. PubMed ID: 33440080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes.
    He YL; Yamaguchi M; Ito H; Terao S; Sekiguchi K
    Int J Clin Pharmacol Ther; 2010 Sep; 48(9):582-95. PubMed ID: 20860912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus.
    Kapur A; O'Connor-Semmes R; Hussey EK; Dobbins RL; Tao W; Hompesch M; Smith GA; Polli JW; James CD; Mikoshiba I; Nunez DJ
    BMC Pharmacol Toxicol; 2013 May; 14():26. PubMed ID: 23668634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of pharmacokinetic and pharmacodynamic parameters following single dose of sitagliptin in healthy Indian males.
    Sangle GV; Patil M; Deshmukh NJ; Shengule SA; Kamble S; Vuppalavanchu KK; Kale S; Baig MLA; Singh G; Shaikh J; Tripathi J; Aravindababu P
    Eur J Clin Pharmacol; 2018 May; 74(5):561-569. PubMed ID: 29511780
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
    O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
    Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of cetagliptin as monotherapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial.
    Ji L; Lu J; Gao L; Ying C; Sun J; Han J; Zhao W; Gao Y; Wang K; Zheng X; Xie D; Ding J; Zhao J; Yu Q; Wang T
    Diabetes Obes Metab; 2023 Dec; 25(12):3671-3681. PubMed ID: 37661308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin.
    Migoya EM; Stevens CH; Bergman AJ; Luo WL; Lasseter KC; Dilzer SC; Davies MJ; Wagner JA; Herman GA
    Can J Clin Pharmacol; 2009; 16(1):e165-70. PubMed ID: 19221403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease.
    McCormick LM; Kydd AC; Read PA; Ring LS; Bond SJ; Hoole SP; Dutka DP
    Circ Cardiovasc Imaging; 2014 Mar; 7(2):274-81. PubMed ID: 24503784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized clinical trial to evaluate the single-dose pharmacokinetics, pharmacodynamics, and safety of sitagliptin in pediatric patients with type 2 diabetes.
    Fraser IP; Neufeld ND; Fox LA; Kipnes MS; Miller TL; Zeitler PS; Rodriguez H; Gilmartin JH; Lee SJ; Patterson JK; Li XS; Maganti L; Luo WL; Tatosian DA; Stoch SA
    Pediatr Diabetes; 2019 Feb; 20(1):48-56. PubMed ID: 30346099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Very short-term effects of the dipeptidyl peptidase-4 inhibitor sitagliptin on the secretion of insulin, glucagon, and incretin hormones in Japanese patients with type 2 diabetes mellitus: analysis of meal tolerance test data.
    Murai K; Katsuno T; Miyagawa J; Matsuo T; Ochi F; Tokuda M; Kusunoki Y; Miuchi M; Namba M
    Drugs R D; 2014 Dec; 14(4):301-8. PubMed ID: 25420579
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes.
    Katz LB; Gambale JJ; Rothenberg PL; Vanapalli SR; Vaccaro N; Xi L; Sarich TC; Stein PP
    Diabetes Obes Metab; 2012 Aug; 14(8):709-16. PubMed ID: 22340428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dipeptidyl-peptidase 4 inhibition and the vascular effects of glucagon-like peptide-1 and brain natriuretic peptide in the human forearm.
    Devin JK; Pretorius M; Nian H; Yu C; Billings FT; Brown NJ
    J Am Heart Assoc; 2014 Aug; 3(4):. PubMed ID: 25158865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects.
    Frost C; Wang J; Nepal S; Schuster A; Barrett YC; Mosqueda-Garcia R; Reeves RA; LaCreta F
    Br J Clin Pharmacol; 2013 Feb; 75(2):476-87. PubMed ID: 22759198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dipeptidyl Peptidase-4 Inhibition Potentiates Stimulated Growth Hormone Secretion and Vasodilation in Women.
    Wilson JR; Brown NJ; Nian H; Yu C; Bidlingmaier M; Devin JK
    J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29478970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study.
    Migoya EM; Miller JL; Gutierrez M; Zheng W; Johnson-Levonas AO; Liu Q; Matthews CZ; Wagner JA; Gottesdiener KM
    Clin Drug Investig; 2010; 30(12):855-66. PubMed ID: 20923244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Henagliflozin, a Novel Selective Inhibitor of Sodium-Glucose Cotransporter 2, in Healthy Subjects Following Single- and Multiple-dose Administration.
    Zhang YF; Liu YM; Yu C; Wang YT; Zhan Y; Liu HY; Zou JJ; Jia JY; Chen Q; Zhong DF
    Clin Ther; 2021 Feb; 43(2):396-409. PubMed ID: 33454124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.